Dosing & Uses
COVID-19 (Investigational)
Investigational treatment of critically ill patients with COVID-19 who have respiratory failure
Next:
Pharmacology
Mechanism of Action
Synthetic analog of vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects
VIP binds specifically to alveolar type II cells (ATII) in lung alveolus, where it elicits anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation
Stimulates ATII cells to make surfactant that must coat the lining of the lungs in order for them to exchange oxygen with the blood; loss of surfactant causes respiratory failure and alveolar collapse, which are hallmarks of COVID-19
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
